SciCombinator

Discover the most talked about and latest scientific content & concepts.

SN Ladhani, MP Slack, NJ Andrews, PA Waight, R Borrow and E Miller
Abstract
We assessed known risk factors, clinical presentation, and outcome of invasive pneumococcal disease (IPD) in children 3-59 months of age after introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in England and Wales. During September 2006-March 2010, a total of 1,342 IPD episodes occurred in 1,332 children; 14.9% (198/1,332) had comorbidities. Compared with IPD caused by PCV7 serotypes (44/248; 17.7%), comorbidities were less common for the extra 3 serotypes in the 10-valent vaccine (15/299; 5.0%) but similar to the 3 additional PCV13 serotypes (45/336; 13.4%) and increased for the 11 extra serotypes in 23-valent polysaccharide vaccine (PPV23) (39/186; 21.0%) and non-PPV23 serotypes (38/138; 27.5%). Fifty-two (3.9%) cases resulted from PCV7 failure; 9 (0.7%) case-patients had recurrent IPD. Case-fatality rate was 4.4% (58/1,332) but higher for meningitis (11.0%) and children with comorbidities (9.1%). Thus, comorbidities were more prevalent in children with IPD caused by non-PCV13 serotypes and were associated with increased case fatality.
Tweets*
2
Facebook likes*
3
Reddit*
0
News coverage*
1
Blogs*
0
SC clicks
0
Concepts
Vaccination schedule, Pneumococcal vaccine, Meningitis, Vaccine, Pneumonia, Pneumococcal polysaccharide vaccine, Streptococcus pneumoniae, Pneumococcal conjugate vaccine
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com